Latest

FDA's Helping Hand to Small Pharma

FDA's Brenda Stodart outlines the services of the Agency's Small Business and Industry Assistance (SBIA) Program.

Pharm Exec's Top 50 Companies 2016

Pharm Exec’s 16th annual listing of the top biopharma players points to important transitions taking place in the larger business model.

Severe Turbulence Ahead for Pharma and for Europe

The UK's Brexit vote has unleashed turbulence in Europe — not least on its pharma sector. Reflector reports.

New & Noteworthy

How One Pollster Correctly Predicted Brexit

Only one polling company correctly predicted the UK's Brexit outcome. Graeme Hutton reports.

Realizing the Potential of Asia-Pacific

Companies that want to tap into the full potential of Asia-Pac must boost the role of their regional headquarters.

Diversity and Inclusion: A Pharma 50 Perspective

Biopharma’s diversity commitment remains a work in progress but the benefits—in measurable ROI—are increasingly clear.

Swerving the Talent Trap

Highly skilled pharma staff are spending too much time on the routine updating of product information. Technology can free them, writes Dr. Jutta Hohenhörst.

Market Access in Europe: Building Health Equity Through Better Outcomes

A new industry working group explores alternative drug funding options in Europe.

Sales & Marketing

Microsoft Means Business with LinkedIn

Last month Microsoft bought LinkedIn. What does this mean for pharm execs using the platform? Peter Houston reports.

Snapchat: A Platform for Pharma Marketing?

Is Snapchat just for fun, or should pharma marketers be taking it seriously as a media platform? Peter Houston takes a look.

Facebook’s New Algorithm: Attention, Engagement and World Domination

Facebook is the number one social-media network for businesses. Peter Houston asks, How can pharma stay relevant in the feed?

Featured E-Books

 

Securing the Global Supply Chain: Strategies for Operational Excellence

Strategic management of the supply chain is vital to winning with customers. Cost and quality are important, but they are not the only things customers care about: New services, flexibility in  relationships, supply reliability, and creatively overcoming obstacles in delivery of products are also core values. Pharmaceutical product portfolios and customers are becoming more complex. To stay ahead, customer-focused supply-chain capabilities is becoming an increasingly crucial part of a company’s competitive advantage. Visit the resource center.

 

The Changing Contours of Drug Commercialization

"The Changing Contours of Drug Commercialization," a new e-book from the editors of Pharmaceutical Executive, sheds light on solutions and strategies uniquely within a manufacturer's own sphere of control that can help navigate the often unforgiving transition from registration to the real-world battle for clinical acceptance and market share. Visit the resource center.  

 

Patient-Centric Approach to Product Commercialization

The industry's much talked-about patient-centered approach requires more than lip-service and organizational redesigns. In order for the patient to emerge center stage in a commercial approach, it's necessary for manufacturers to shift prioritization's to help the greatest number of patients gain access and remain on treatments.

 

The Path To Market Access: Winning Strategies To Build Value With Payers

Success in today’s rapidly changing market access world depends on understanding your product’s value through the eyes of payers and shaping crucial value communication around the needs of market access stakeholders as much as it does on developing solid evidence of the value of your product.

 

 

View all e-books

PEspeaks

Microsoft Means Business with LinkedIn

Last month Microsoft bought LinkedIn. What does this mean for pharm execs using the platform? Peter Houston reports.

“Have We Met Your Needs Today?” Patient Centricity is So Much More than a Customer Satisfaction Survey [SPONSORED]

Pam Garfield, SVP at Patient Health Perspectives, explores how patient centricity can improve trial design and outcomes when embraced fully with commitment to the patient perspective.

Brexit Blues: What Now for UK Life Sciences?

Leela Barham looks at the implications for the UK industry in the aftermath of last week's vote for Brexit.

EFPIA and APBI Give Statement on Brexit

EU and UK industry groups did their best to display calm and confidence as the world woke up to the reality of Brexit.

Interviews

AZ Seizes the "Mobile Moment"

Pharm Exec talks to AstraZeneca's Jenny Streets about the new AZHelps mobile and social media platform.

Q&A: Research Data Promise vs. Reality

Ken Getz of the Tufts Center for the Study of Drug Development outlines how the convergence of health data and technology will be key to lasting gains for clinical research.

Steering the Change: GSK's Jack Bailey

Pharm Exec speaks with GlaxoSmithKline's US Pharmaceuticals head Jack Bailey.

HBA's Woman of the Year 2016

Pharm Exec profiles Roche’s Jennifer Cook, this year’s winner of the Healthcare Businesswomen’s Association (HBA) Woman of the Year award.

Information in Action: DIA's Barbara Lopez Kunz

William Looney speaks with DIA's Global Chief Executive to see how the organization is repositioning itself.

Regulatory

Severe Turbulence Ahead for Pharma and for Europe

The UK's Brexit vote has unleashed turbulence in Europe — not least on its pharma sector. Reflector reports.

Brexit Blues: What Now for UK Life Sciences?

Leela Barham looks at the implications for the UK industry in the aftermath of last week's vote for Brexit.

Swerving the Talent Trap

Highly skilled pharma staff are spending too much time on the routine updating of product information. Technology can free them, writes Dr. Jutta Hohenhörst.

From the Editor

Design that Delivers

William Looney explores the power of workplace aesthetic on the intangibles of culture, morale — and corporate mission.

Pharm Exec at the Vantage Point

The Boston biotech cluster proved an ideal setting for Pharm Exec's recent annual Editorial Advisory Board meeting. William Looney reports.

The Odd Couple

The challenges facing the ad industry and big Pharma are remarkably similar—a point driven home by four distinct themes discussed at this year's 4A's Transformation conference.

lorem ipsum